Sapporo Higashi Tokushukai Hospital

Sapporo 065-0033

3 studies enrolling now · 21 studies all time

What they study most

Acute Coronary Syndrome, Colitis, Ulcerative, Crohn Disease, Crohn's Disease, Fistulizing Crohns Disease, Inflammatory Bowel Diseases, Perianal Crohns Disease, Ulcerative Colitis, Ulcerative Colitis (UC), Ulcerative Colitis Chronic, Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe

Studies at this site

• LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease — Running, not enrolling
• A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis — Running, not enrolling
• A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) — Running, not enrolling
• A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease — Stopped early
• A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) — Completed
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease — Completed
• OPTIMIZE IDE for the Treatment of ACS — Stopped early
• Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) — Stopped early
• An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis — Completed
• Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis — Stopped early
• Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305) — Stopped early
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis — Completed